Skip to main content

PRELUDE CAPITAL MANAGEMENT, LLC

Position in ESPR — Esperion Therapeutics, Inc.

CIK 1387508 NEW YORK, NY

Position in ESPR

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$0
+$0 QoQ
Shares Held
213,636
+1263.3% QoQ
Ownership
0.083%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Dec 2023
11 quarters on record
Voting authority Sole 0% Shared 100% None 0%

Common Shares in ESPR Over Time

Shares Held

Position Value (USD)

Derivatives in ESPR

reported options exposure · as of Sep 30, 2024
CallValue
$0
CallShares
34,800
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - Specialty & Generic

Healthcare · as of Jun 30, 2026

PRELUDE CAPITAL MANAGEMENT, LLC holds $20,247,336 across 16 Drug Manufacturers - Specialty & Generic names. ESPR ranks #16 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in ESPR

Export CSV
12 filing rows on record
Report Date Value (USD) Shares
2026-06-30 213,636
2026-03-31 15,670
2025-12-31 27,058
2025-09-30 65,327
2025-06-30 265,588
2025-03-31 168,305
2024-12-31 119,675
2024-09-30 34,800
2024-09-30 242,847
2024-06-30 270,889
2024-03-31 27,963
2023-12-31 29,791